BioDlink International Company Limited
1875.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.58B
Close$
Share Statistics
| Market cap | $2.58 Billion |
|---|---|
| Enterprise Value | $2.70 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.14 |
| Beta | -0.13 |
| Outstanding Shares | 725,197,000 |
Return
| Return on Equity | -25.20% |
|---|---|
| Return on Assets | -13.20% |
| Return on Invested Capital | -12.87% |
Valuation & Multiples
| P/E Ratio | -13.8 |
|---|---|
| PEG | 0.91 |
| Price to Sales | 1.78 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.72 |
| Enterprise Value to EBIT | -22.25 |
| Enterprise Value to Net Income | -18 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 0.61 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 21, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BioDlink International Company Limited
596 employees
CEO: Shan Fu BioDlink International Co., Ltd. operates as a clinical-stage biopharmaceutical firm, dedicating its resources to the development and future commercialization of novel oncology drugs and therapeutic solutions. Its pipeline features sever...